摘要
2024年ASCO-CU年会在前列腺癌领域重点聚焦于转移性去势抵抗性前列腺癌(mCRPC)的精准诊治。各项研究结果显示,基于分子分型指导的治疗方案可显著延长患者生存期。同时国内也在积极探索基于基因检测的个体化治疗方案。未来基于基因检测的精准治疗将成为mCRPC治疗的重要方向。
The 2024 ASCO-GU Annual Meeting focused on precision diagnosis and treatment of metastatic castration-resistant prostate cancer(mCRPC).Studies showed that treatment strategies guided by molecular subtyping significantly prolonged patient survival.Meanwhile,China is actively exploring personalized treatment plans based on genetic testing.In the future,precision treatment based on genetic testing will be a crucial direction in mCRPC therapy.
作者
董柏君
沈朋飞
曾浩
薛蔚
Dong Baijun;Shen Pengfei;Zeng Hao;Xue Wei(Department of Urology,Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Department of Urology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2024年第4期261-264,共4页
Chinese Journal of Urology
